Health
Lilly’s Weight-Loss Drug Zepbound Slashed Heart Failure Risks in Study
- Trial is first to establish Zepbound’s cardiovascular benefits
- Deaths, hospital stays, other risks fell 38% versus placebo
An Eli Lilly & Co. Zepbound injection pen.
Photographer: Shelby Knowles/BloombergThis article is for subscribers only.
Eli Lilly & Co.’s blockbuster Zepbound improved the long-term health of patients with obesity-related heart failure in a study, illuminating the cardiovascular benefits of the weight-loss shot.
The risk of death, hospitalization and other bad outcomes was 38% lower in patients given Zepbound compared to those who received a placebo, Lilly said Thursday. The drug also significantly reduced heart failure symptoms, including shortness of breath, fatigue and an irregular heartbeat.